普罗布考联合冠心病二级预防对老年陈旧性心肌梗死患者氧化应激指标及心功能的影响

摘要
图/表
参考文献(19)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨普罗布考联合冠心病二级预防对老年陈旧性心肌梗死患者氧化应激指标及心功能的影响。方法选取2019年10月至2021年1月厦门大学附属成功医院收治的86 例老年性陈旧性心肌梗死患者作为研究对象，按照随机数字表法分为观察组（43 例）与对照组（43 例）。对照组采用冠心病二级预防方案，观察组在对照组的基础上给予普罗布考治疗。比较两组患者的氧化应激指标[超氧化物歧化酶（SOD）、丙二醛（MDA）、谷胱甘肽过氧化物酶（GSH-Px）]，超声心动图指标[左心室射血分数（LVEF）、心排血量（CO）、心排血指数（CI）及平均肺动脉压]、心功能分级及治疗期间的不良反应发生情况。结果两组患者治疗后的SOD、GSH-Px 水平高于治疗前，且观察组治疗后的SOD、GSH-Px 水平高于对照组，差异有统计学意义（P＜0.05）；两组患者治疗后的MDA 水平低于治疗前，且观察组治疗后的MDA 水平低于对照组，差异有统计学意义（P＜0.05）。两组患者治疗后的LVEF、CO、CI水平高于治疗前，且观察组治疗后的LVEF、CO、CI 高于对照组，差异有统计学意义（P＜0.05）；两组患者治疗后的平均肺动脉压低于治疗前，且观察组治疗后的平均肺动脉压低于对照组，差异有统计学意义（P＜0.05）。两组患者治疗后的心功能分级优于治疗前，且观察组治疗后的心功能分级情况优于对照组，差异有统计学意义（P＜0.05）。两组患者治疗期间的不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论普罗布考联合冠心病二级预防能显著降低老年陈旧性心肌梗死患者的氧化应激水平，改善心功能及患者预后，安全性较好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	钟素
	余研

关键词 ：普罗布考, 二级预防, 老年, 陈旧性心肌梗死

Abstract： Objective To investigate the influence of Probucol combined with secondary prevention of coronary heart disease on oxidative stress indexes and cardiac function in elderly patients with old myocardial infarction. Methods A total of 86 elderly patients with old myocardial infarction treated in Chenggong Hospital Affiliated to Xiamen University from October 2019 to January 2021 were selected as the research objects. According to random number table method,they were divided into the observation group (43 cases) and the control group (43 cases). The control group was treated with secondary prevention of coronary heart disease, and the observation group was treated with Probucol on the basis of the control group. The oxidative stress indexes (superoxide dismutase [SOD], malondialdehyde [MDA], glutathione peroxidase [GSH-Px]), echocardiographic indexes (left ventricular ejection fraction [LVEF], cardiac output [CO], cardiac output index [CI] and the mean pulmonary artery pressure), cardiac function grade, adverse reactions during treatment were compared between the two groups. Results The levels of SOD and GSH-Px in the two groups after treatment were higher than those before treatment, and the levels of SOD and GSH-Px in the observation group after treatment were higher than those in the control group, the differences were statistically significant (P＜0.05). The MDA levels of the two groups after treatment were lower than those before treatment, and the MDA level of the observation group after treatment was lower than that of the control group, the differences were statistically significant (P＜0.05). The levels of LVEF, CO and CI in the two groups after treatment were higher than those before treatment, and the levels of LVEF, CO and CI in the observation group after treatment were higher than those in the control group, the differences were statistically significant (P＜0.05). The levels of mean pulmonary artery pressure of the two groups after treatment were lower than those before treatment, and the mean pulmonary artery pressure of the observation group after treatment was lower than that of the control group, the differences were statistically significant (P＜0.05). The cardiac function grading of the two groups after treatment was better than that before treatment, and the cardiac function grading of the observation group after treatment was better than that of the control group, the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups during treatment (P＞0.05). Conclusion Probucol combined with secondary prevention of coronary heart disease can significantly reduce the level of oxidative stress, improve cardiac function and prognosis in elderly patients with old myocardial infarction, and has good safety.

Key words： Probucol Secondary prevention Elderly Old myocardial infarction

基金资助:福建省卫生计生科研人才培养项目（2018-2-88）。

作者简介: 钟素（1989-），女，硕士，研究方向：老年医学心血管。

引用本文:

钟素；余研. 普罗布考联合冠心病二级预防对老年陈旧性心肌梗死患者氧化应激指标及心功能的影响[J]. 中国当代医药, 2022, 29(16): 83-86转90.
ZHONG Su；YU Yan. Influence of Probucol combined with secondary prevention of coronary heart disease on oxidative stress indexes and cardiac function in elderly patients with old myocardial infarction. 中国当代医药, 2022, 29(16): 83-86转90.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I16/83

[14]	刘晓丽，王雪，殷倩，等.SOD 水平与急性心肌梗死血运重建患者远期心室重构的相关性[J].心脏杂志，2016，28（2）：182-184.
[15]	毛海慧，张丹，王菊飞，等.抗氧化治疗联合二级预防对老年陈旧性心肌梗死氧化应激及预后的影响[J].浙江医学，2019，41（21）：2292-2296.
[16]	高巧营，刘晋津，吴腾，等.普罗布考联合山莨菪碱对糖尿病大鼠对比剂肾损伤的影响[J].山东医药，2017，57（46）：7-11.
[17]	王新云，黄晓明，阳维德，等.抗氧化治疗对防治急性心肌梗死患者远期心室重构的临床研究[J].中国医院药学杂志，2017，37（12）：1182-1184，1188.
[1]	李倩，臧渝梨.急性心肌梗死临床症状的研究进展[J].当代护士（下旬刊），2020，27（3）：11-13.
[2]	黄小花.心电图对陈旧性心肌梗死的诊断及漏诊原因分析[J].临床合理用药杂志，2019，12（7）：164-165.
[3]	葛均波，戴宇翔.中国非ST 段抬高型急性冠状动脉综合征诊断和治疗现状[J].浙江医学，2017，39（13）：1045-1047，1052.
[4]	袁鹰，何平，汤祥瑞，等.KLF9 通过增加氧化应激对心肌细胞缺血损伤的影响[J].中国循证心血管医学杂志，2020，12（10）：1190-1194.
[5]	曹珊珊，侯禹辰，张大庆.普罗布考在动脉粥样硬化心血管疾病防治中的再认识[J].实用药物与临床，2018，21（8）：951-957.
[6]	Levine GN，Bates ER，Blankenship JC，et al.2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction：an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction[J].J Am Coll Cardiol，2016，67（10）：1235-1250.
[7]	Yap J，Lim FY，Gao F，et al.Correlation of the New York Heart Association Classification and the 6-minute walk distance：a systematic review[J].Clin Cardiol，2015，38（10）：621-628.
[8]	霍奇文，杜少英，杨慧，等.冠心病病人二级预防依从性及其影响因素分析[J].护理研究，2019，33（15）：2590-2595.
[9]	刘冰.普罗布考联合替罗非班在冠心病经皮冠状动脉介入治疗中的应用[J].社区医学杂志，2017，15（19）：38-40.
[10]	王传杰，于爱东，岳海静，等.抗氧化疗法对急性心肌梗死患者的长期疗效研究[J].湖南师范大学学报（医学版），2018，15（3）：126-128.
[11]	王哲，王秋实，刘晓玉，等.糖基化终末产物调节氧化应激影响脐血间充质干细胞增殖及普罗布考保护作用[J].实用药物与临床，2013，16（4）：273-276.
[12]	卢小岚，张晓，朱记法，等.血β2-MG、CysC、SOD 水平与冠状动脉血管病变的关系[J].中国实用医刊，2017，44（9）：20-23.
[13]	沈云峰，胡远贵，张洪波，等.冠心病患者血清胱抑素C、一氧化氮、超氧化物歧化酶及超敏C 反应蛋白水平变化及与冠脉狭窄程度的相关性[J].微循环学杂志，2014，24（3）：28-31.
[18]	李云攀，刘美云，赵雯娜，等.瑞舒伐他汀联合普罗布考对大鼠动脉粥样硬化炎症与氧化应激的干预效果[J].中国循证心血管医学杂志，2014，6（3）：352-355.
[19]	崔源源，王欣，赵福海.抗氧化剂普罗布考对冠心病介入后患者主要不良心血管事件的Meta 分析[J].中国动脉硬化杂志，2019，27（12）：1045-1052.